{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T06:14:24Z","timestamp":1788588864661,"version":"build-2803163510"},"update-to":[{"DOI":"10.1371\/journal.pbio.3001384","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000}}],"reference-count":43,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T00:00:00Z","timestamp":1639612800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"national institute of allergy and infectious diseases","doi-asserted-by":"publisher","award":["HHSN272201400008C"],"award-info":[{"award-number":["HHSN272201400008C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007457","name":"jpb foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007457","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014895","name":"open philanthropy project","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014895","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosbiology.org"],"crossmark-restriction":false},"short-container-title":["PLoS Biol"],"abstract":"<jats:p>Vaccines against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) have been highly efficient in protecting against Coronavirus Disease 2019 (COVID-19). However, the emergence of viral variants that are more transmissible and, in some cases, escape from neutralizing antibody responses has raised concerns. Here, we evaluated recombinant protein spike antigens derived from wild-type SARS-CoV-2 and from variants B.1.1.7, B.1.351, and P.1 for their immunogenicity and protective effect in vivo against challenge with wild-type SARS-CoV-2 in the mouse model. All proteins induced high neutralizing antibodies against the respective viruses but also induced high cross-neutralizing antibody responses. The decline in neutralizing titers between variants was moderate, with B.1.1.7-vaccinated animals having a maximum fold reduction of 4.8 against B.1.351 virus. P.1 induced the most cross-reactive antibody responses but was also the least immunogenic in terms of homologous neutralization titers. However, all antigens protected from challenge with wild-type SARS-CoV-2 in a mouse model.<\/jats:p>","DOI":"10.1371\/journal.pbio.3001384","type":"journal-article","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T18:53:38Z","timestamp":1639680818000},"page":"e3001384","update-policy":"https:\/\/doi.org\/10.1371\/journal.pbio.corrections_policy","source":"Crossref","is-referenced-by-count":20,"title":["Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8029-8227","authenticated-orcid":true,"given":"Fatima","family":"Amanat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirin","family":"Strohmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip S.","family":"Meade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Dambrauskas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5314-8530","authenticated-orcid":true,"given":"Barbara","family":"M\u00fchlemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Vigdorovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Noah","family":"Sather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9880-6560","authenticated-orcid":true,"given":"Lynda","family":"Coughlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4121-776X","authenticated-orcid":true,"given":"Florian","family":"Krammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,12,16]]},"reference":[{"issue":"2","key":"pbio.3001384.ref001","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4161\/rna.8.2.15013","article-title":"Coronaviruses: an RNA proofreading machine regulates replication fidelity and diversity","volume":"8","author":"MR Denison","year":"2011","journal-title":"RNA Biol"},{"issue":"5","key":"pbio.3001384.ref002","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2021.26.5.210009","article-title":"Preliminary report of an outbreak of SARS-CoV-2 in mink and mink farmers associated with community spread, Denmark, June to November 2020","volume":"26","author":"HD Larsen","year":"2021","journal-title":"Euro Surveill"},{"key":"pbio.3001384.ref003","article-title":"Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity","author":"EC Thomson","year":"2021","journal-title":"Cell"},{"issue":"4","key":"pbio.3001384.ref004","first-page":"812","article-title":"Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19","volume":"182","author":"B Korber","year":"2020","journal-title":"Virus. Cell"},{"key":"pbio.3001384.ref005","unstructured":"PHE. Investigation of novel SARS-CoV-2 variant Variant of Concern 202012\/01 Technical briefing 5. Available from: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/959426\/Variant_of_Concern_VOC_202012_01_Technical_Briefing_5.pdf2021."},{"issue":"7854","key":"pbio.3001384.ref006","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/s41586-021-03402-9","article-title":"Detection of a SARS-CoV-2 variant of concern in South Africa","volume":"592","author":"H Tegally","year":"2021","journal-title":"Nature"},{"issue":"6544","key":"pbio.3001384.ref007","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1126\/science.abh2644","article-title":"Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil.","volume":"372","author":"NR Faria","year":"2021","journal-title":"Science"},{"key":"pbio.3001384.ref008","article-title":"SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2","author":"F Amanat","year":"2021","journal-title":"Cell"},{"key":"pbio.3001384.ref009","article-title":"N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2","author":"M McCallum","year":"2021","journal-title":"Cell"},{"issue":"6504","key":"pbio.3001384.ref010","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1126\/science.abc6952","article-title":"A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2","volume":"369","author":"X Chi","year":"2020","journal-title":"Science"},{"issue":"1","key":"pbio.3001384.ref011","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.chom.2020.11.007","article-title":"Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition","volume":"29","author":"AJ Greaney","year":"2021","journal-title":"Cell Host Microbe"},{"issue":"7821","key":"pbio.3001384.ref012","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41586-020-2456-9","article-title":"Convergent antibody responses to SARS-CoV-2 in convalescent individuals","volume":"584","author":"DF Robbiani","year":"2020","journal-title":"Nature"},{"key":"pbio.3001384.ref013","article-title":"A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2","author":"WB Alsoussi","year":"2020","journal-title":"Infection. J Immunol"},{"key":"pbio.3001384.ref014","article-title":"SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses","author":"O Turner JS","year":"2021","journal-title":"Nature"},{"key":"pbio.3001384.ref015","article-title":"Escape of SARS-CoV-2 501Y.V2 variants from neutralization by convalescent plasma","author":"S Cele","year":"2021","journal-title":"medRxiv"},{"key":"pbio.3001384.ref016","article-title":"Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2","author":"DA Collier","year":"2021","journal-title":"Nature"},{"issue":"4","key":"pbio.3001384.ref017","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.chom.2021.03.009","article-title":"Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant","volume":"29","author":"VV Edara","year":"2021","journal-title":"Cell Host Microbe"},{"issue":"11","key":"pbio.3001384.ref018","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1016\/j.cell.2021.03.055","article-title":"Antibody evasion by the P.1 strain of SARS-CoV-2","volume":"184","author":"W Dejnirattisai","year":"2021","journal-title":"Cell"},{"key":"pbio.3001384.ref019","article-title":"Vaccination NSGfC-. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants","author":"LJ Abu-Raddad","year":"2021","journal-title":"N Engl J Med"},{"key":"pbio.3001384.ref020","article-title":"Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant","author":"V Shinde","year":"2021","journal-title":"N Engl J Med"},{"issue":"20","key":"pbio.3001384.ref021","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1056\/NEJMoa2102214","article-title":"Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant","volume":"384","author":"SA Madhi","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"pbio.3001384.ref022","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1002\/cpmc.108","article-title":"An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening","volume":"58","author":"F Amanat","year":"2020","journal-title":"Curr Protoc Microbiol"},{"issue":"5682","key":"pbio.3001384.ref023","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1126\/science.1097211","article-title":"Mapping the antigenic and genetic evolution of influenza virus","volume":"305","author":"DJ Smith","year":"2004","journal-title":"Science"},{"issue":"10293","key":"pbio.3001384.ref024","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(21)01358-1","article-title":"Collaborators PHSatEI. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness","volume":"397","author":"A Sheikh","year":"2021","journal-title":"Lancet"},{"key":"pbio.3001384.ref025","article-title":"Effectiveness of COVID-19 vaccines against the B.1.617.2 variant.","author":"JL Bernal","year":"2021","journal-title":"medRxiv"},{"key":"pbio.3001384.ref026","article-title":"Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum","author":"C Liu","year":"2021","journal-title":"Cell"},{"key":"pbio.3001384.ref027","doi-asserted-by":"crossref","first-page":"103626","DOI":"10.1016\/j.ebiom.2021.103626","article-title":"Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients","volume":"73","author":"JM Carre\u00f1o","year":"2021","journal-title":"EBioMedicine"},{"key":"pbio.3001384.ref028","article-title":"Evidence for antibody as a protective correlate for COVID-19 vaccines","author":"KA Earle","year":"2021","journal-title":"Vaccine"},{"key":"pbio.3001384.ref029","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","author":"DS Khoury","year":"2021","journal-title":"Nat Med"},{"key":"pbio.3001384.ref030","article-title":"Negligible impact of SARS-CoV-2 variants on CD4+ and CD8+ T cell reactivity in COVID-19 exposed donors and vaccinees","author":"A Tarke","year":"2021","journal-title":"bioRxiv"},{"issue":"2","key":"pbio.3001384.ref031","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nm.3443","article-title":"Broadly neutralizing hemagglutinin stalk-specific antibodies require Fc\u03b3R interactions for protection against influenza virus in vivo","volume":"20","author":"DJ Dilillo","year":"2014","journal-title":"Nat Med"},{"issue":"11","key":"pbio.3001384.ref032","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/s41590-018-0233-9","article-title":"Antibody-mediated protection against Ebola virus","volume":"19","author":"EO Saphire","year":"2018","journal-title":"Nat Immunol"},{"issue":"4","key":"pbio.3001384.ref033","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.cell.2018.07.033","article-title":"Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection","volume":"174","author":"EO Saphire","year":"2018","journal-title":"Cell"},{"issue":"6","key":"pbio.3001384.ref034","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01696-18","article-title":"Broadly Cross-Reactive, Nonneutralizing Antibodies against Influenza B Virus Hemagglutinin Demonstrate Effector Function-Dependent Protection against Lethal Viral Challenge in Mice","volume":"93","author":"G Asthagiri Arunkumar","year":"2019","journal-title":"J Virol"},{"issue":"7","key":"pbio.3001384.ref035","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/s41591-020-0913-5","article-title":"A serological assay to detect SARS-CoV-2 seroconversion in humans","volume":"26","author":"F Amanat","year":"2020","journal-title":"Nat Med"},{"issue":"81","key":"pbio.3001384.ref036","first-page":"e51112","article-title":"Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system.","author":"I Margine","year":"2013","journal-title":"J Vis Exp"},{"issue":"2","key":"pbio.3001384.ref037","doi-asserted-by":"crossref","first-page":"e02556","DOI":"10.1128\/mBio.02556-14","article-title":"Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice","volume":"6","author":"TJ Wohlbold","year":"2015","journal-title":"mBio"},{"issue":"4","key":"pbio.3001384.ref038","doi-asserted-by":"crossref","first-page":"100253","DOI":"10.1016\/j.xcrm.2021.100253","article-title":"Rapid decline of neutralizing antibodies is associated with decay of IgM in adults recovered from mild COVID-19","volume":"2","author":"WE Harrington","year":"2021","journal-title":"Cell Rep Med"},{"key":"pbio.3001384.ref039","article-title":"SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2","author":"F Amanat","year":"2021","journal-title":"Cell"},{"key":"pbio.3001384.ref040","article-title":"Comparison of Transgenic and Adenovirus hACE2 Mouse Models for SARS-CoV-2 Infection","author":"R Rathnasinghe","year":"2020","journal-title":"bioRxiv"},{"issue":"5","key":"pbio.3001384.ref041","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01741-19","article-title":"Monoclonal Antibodies with Neutralizing Activity and Fc-Effector Functions against the Machupo Virus Glycoprotein","volume":"94","author":"F Amanat","year":"2020","journal-title":"J Virol"},{"issue":"2","key":"pbio.3001384.ref042","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02648-20","article-title":"Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the Mouse Model.","volume":"12","author":"F Amanat","year":"2021","journal-title":"mBio"},{"key":"pbio.3001384.ref043","doi-asserted-by":"crossref","first-page":"103132","DOI":"10.1016\/j.ebiom.2020.103132","article-title":"Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate","volume":"62","author":"W Sun","year":"2020","journal-title":"EBioMedicine"}],"updated-by":[{"DOI":"10.1371\/journal.pbio.3001384","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000}}],"container-title":["PLOS Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pbio.3001384","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T19:35:11Z","timestamp":1642102511000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pbio.3001384"}},"subtitle":[],"editor":[{"given":"Sarah L.","family":"Rowland-Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,12,16]]},"references-count":43,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pbio.3001384","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pbio.3001384","asserted-by":"object"}]},"ISSN":["1545-7885"],"issn-type":[{"value":"1545-7885","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,16]]}}}